| First Author | Vandenberg CJ | Year | 2014 |
| Journal | Blood | Volume | 124 |
| Issue | 7 | Pages | 1099-109 |
| PubMed ID | 24986687 | Mgi Jnum | J:214514 |
| Mgi Id | MGI:5603219 | Doi | 10.1182/blood-2014-04-570770 |
| Citation | Vandenberg CJ, et al. (2014) Plasmacytomagenesis in Emu-v-abl transgenic mice is accelerated when apoptosis is restrained. Blood 124(7):1099-109 |
| abstractText | Mice susceptible to plasma cell tumors provide a useful model for human multiple myeloma. We previously showed that mice expressing an Emicro-v-abl oncogene solely develop plasmacytomas. Here we show that loss of the proapoptotic BH3-only protein Bim or, to a lesser extent, overexpression of antiapoptotic Bcl-2 or Mcl-1, significantly accelerated the development of plasmacytomas and increased their incidence. Disease was preceded by an increased abundance of plasma cells, presumably reflecting their enhanced survival capacity in vivo. Plasmacytomas of each genotype expressed high levels of v-abl and frequently harbored a rearranged c-myc gene, probably as a result of chromosome translocation. As in human multiple myelomas, elevated expression of cyclin D genes was common, and p53 deregulation was rare. Our results for plasmacytomas highlight the significance of antiapoptotic changes in multiple myeloma, which include elevated expression of Mcl-1 and, less frequently, Bcl-2, and suggest that closer attention to defects in Bim expression is warranted. |
